ASMS 2020 On-Demand
Miss any of our live events from the ASMS 2020 virtual scientific series? All of these great events are available now on-demand. Experience a brand new technology announcement redefining high-throughput mass spectrometry, the role mass spec is playing in COVID-19 research and new analytical techniques for emerging applications.
Join SCIEX in this exclusive event as we showcase a newly available product that will redefine your idea of high throughput, quantitative mass spectrometry.
Multiple attribute method (MAM) has gained popularity in monitoring biologic PQAs of biotherapeutics within late-stage development and manufacturing laboratories. With the advantage of limited sample preparation and the potential for real-time monitoring, the implementation of MAM for intact mass analysis (including subunit analysis) has attracted a lot of interest in the biopharmaceutical industry. To date, there has not been user-friendly or streamlined software capable of data acquisition, intact mass reconstruction, intact mass MAM and peptide MAM analysis in compliant environments. With the launch of SCIEX OS Software 1.7, SCIEX offers an integrated and compliant solution for both intact and peptide level attribute monitoring. Two liability studies, oxidation stress (LC separation) and high pH stress (CE separation), were employed to demonstrate the application of the SCIEX flexible solution for MAM.
The COVID-19 pandemic has invoked a rapid response from the global scientific community to accelerate research to understand the mechanism of the disease and to develop vaccines and therapies for the well-being of our community. Mass spectrometry has played a critical role in much of this research, from high-throughput proteomics research to understand viral protein interactions with host proteins as a foundation to test potential therapeutic inhibitors, to the development of new antibody therapies that are safe and effective. This seminar will highlight science from leading researchers around the world and showcase how mass spectrometry is a critical tool to support the work of our great scientific community.
Oligonucleotide therapeutics and gene therapies are rapidly gaining attention as their potency improves and delivery challenges are addressed. This is particularly true of the antisense oligonucleotides (ASO) and the small interfering RNA (siRNA) therapeutics. The potential disease areas in which oligonucleotide therapies are being developed is rapidly expanding due to their potential for treating previously undruggable targets. Routine approaches for oligonucleotide bioanalysis have involved hybridization-based ELISA (HELISA) primarily due to the low detection limits that can be achieved. However, hybridization assays lack the specificity to distinguish between the oligonucleotide product and related impurities/metabolites and as such, they cannot be identified and subsequently quantified. Liquid chromatography coupled with high resolution mass spectrometry (LC-HRMS) is an attractive technique for the analysis of oligonucleotide therapeutics. LC-HRMS can effectively discriminate and quantify not only the target analyte but also impurities/metabolites in the sample. The SCIEX TripleTOF® 6600+ LC-MS/MS System combines excellent quantitative performance with the selectivity of HRMS. We’ll demonstrate the quantitative capabilities of both TOF MS and MRMHR scans. The unique quantitative mass reconstruction capabilities within SCIEX OS-Q Software 1.7 are presented, in addition to MRM based workflows for enhanced selectivity. The HRMS benefits of the SCIEX TripleTOF 6600+ LC-MS/MS System are demonstrated for the detection and relative quantification of impurities using TOF MS and the determination of the target sequence with MRMHR.